Oslo, 30 April 2025 – Aker BioMarine has signed an agreement with leading clinical research organization KGK Science Inc., marking the start of preparations for the company’s first clinical trial of Lysoveta. The breakthrough supplement contains LPC (lyso-phosphatidylcholine) and is designed to deliver essential omega-3 fatty acids directly to the brain and eyes.
The agreement marks a significant step forward in the clinical development of Lysoveta and highlights Aker BioMarine’s commitment to advancing science-based solutions for brain and eye health.
“Launching our first clinical study for Lysoveta is a major milestone in our journey to develop new health solutions,” said Simon Seward, CEO of Human Health Ingredients at Aker BioMarine. “We believe that Lysoveta will play an important role in supporting brain and eye health, and this study brings us one step closer to delivering innovative solutions to patients around the world. As part of our broader commitment to healthy ageing, we are focused on developing science-backed products that help people maintain cognitive function, mobility, and quality of life as they age."
About the study
The randomized, placebo-controlled trial will enroll 138 healthy men and women aged 50–75 years who report mild memory complaints. The primary objective is to assess the effect of Lysoveta on cognitive function, with a particular focus on memory domains from baseline to 112 days. Secondary measures include mood, omega-3 status, brain-derived neurotrophic factor (BDNF) levels, and safety parameters.
The study is expected to run for approximately 18 months, with interim results focusing on mood outcomes anticipated in the first quarter of 2026.
KGK Science Inc., renowned for its expertise in cognitive clinical research, will conduct the trial. Aker BioMarine’s manufacturing facilities have been fully scaled to ensure consistent supply throughout the study period.
A new frontier in brain and eye health
Lysoveta represents a new generation of omega-3 innovation. By binding DHA and EPA to lysophosphatidylcholine (LPC), the product is uniquely formulated to cross the blood-brain and blood-retina barriers — critical to delivering key nutrients where they are needed most.
Aker BioMarine holds 40 patents with broad protection relating to the composition, usage, and production of LPC-bound omega-3 products in 16 countries worldwide — demonstrating the company’s leadership and long-term commitment to innovation in this field.
The launch of this study builds on previous collaboration efforts with leading researchers, including Dr. Michael Davidson and Trofi Nutritionals, aiming to expand Lysoveta’s potential use in conditions like Alzheimer’s disease, male infertility, and gestational diabetes.
Lysoveta already holds New Dietary Ingredient (NDI) status in the United States, with regulatory processes ongoing in Europe, China, and Australia.
“This clinical trial represents an important step in translating our scientific research into real-world health solutions. It underscores our commitment to advancing evidence-based innovation that can support brain and eye health”, said Line Johnsen, SVP Human Health Ingredients R&D.
About Aker BioMarine
Aker BioMarine is a leading human health and nutrition innovator that develops krill-derived products for consumer health and nutrition. Krill is a natural, powerful, and health-promoting source of nutrients from the pristine waters of Antarctica, and Aker BioMarine has a unique position in its industry. The ingredient portfolio consists of Superba Krill Oil, Lysoveta, FloraMarine, and PL+, as well as the consumer brand, Kori Krill. The innovative approach also extends into the spin-offs AION (reduce and recycle plastic waste across industries) and Understory (a protein brand). Aker BioMarine is listed on the Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.